SETD4-AS1: A Potential Drug Target and Biomarker (G105369295)

Target Name: SETD4-AS1

NCBI ID: G105369295

SETD4-AS1

Other Name(s): SETD4 antisense RNA 1 | SETD4-AS1 variant X2

SETD4-AS1: A Potential Drug Target and Biomarker

SETD4 (Splice Enhancer of DNA-Binding proteins 4) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression and DNA replication. It is a key player in the process of splicing, which is the process by which the cell removes non-coding regions from the RNA molecule and replaces them with the appropriate coding regions. DNA-binding proteins, such as SETD4, are involved in the regulation of gene expression by binding to specific DNA sequences.

Recent studies have identified SETD4 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. This is due to its involvement in the regulation of gene expression and its ability to interact with various signaling pathways.

Potential Drug Target

SETD4 has been identified as a potential drug target due to its involvement in the regulation of cell growth and its ability to interact with various signaling pathways. It has been shown to play a role in the regulation of cell proliferation, cell survival, and cell differentiation.

Furthermore, SETD4 has been shown to interact with various signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT signaling pathways. These signaling pathways are involved in the regulation of cell growth, differentiation, and survival, making SETD4 a promising target for drug development.

Biomarker

SETD4 has also been identified as a potential biomarker for various diseases, including cancer. Its involvement in the regulation of gene expression and its ability to interact with various signaling pathways make it an attractive target for cancer diagnosis and treatment.

Studies have shown that high levels of SETD4 are associated with the development and progression of cancer. Additionally, inhibition of SETD4 has been shown to inhibit the growth and survival of cancer cells. This suggests that SETD4 may be a useful biomarker for the diagnosis and treatment of cancer.

Conclusion

SETD4 is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression and DNA replication. Its involvement in the regulation of cell growth and its ability to interact with various signaling pathways make it a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Further research is needed to fully understand the role of SETD4 in disease progression and the development of new treatments. However, its potential as a drug target and biomarker makes it an attractive target for future research and development.

Protein Name: SETD4 Antisense RNA 1

The "SETD4-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SETD4-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets